Article

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic Resistance

2026-02-08

Abstract excerpt

Acquired resistance to osimertinib remains a major challenge in treating EGFR-mutant (EGFR+) Non-Small-Cell Lung Cancer (NSCLC). Although most patients initially respond to treatment, relapses are universal, even after prolonged remission during which tumor dormancy occurs. Here, we show that osimertinib induces and maintains senescence in EGFR+ NSCLC. Importantly, osimertinib does not kill senescent cells; howeve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 06de409c-b86a-51c8-9651-af3e3c9b69e2
DOI: 10.64898/2026.02.07.704600

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic ResistanceDOI 10.64898/2026.02.07.704600Read

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instabilitySemantic proximity Read

Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.Semantic proximity Read

Oncogene inactivation-induced senescence facilitates tumor relapseSemantic proximity Read

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibSemantic proximity Read

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in <i>EGFR</i> -mutant NSCLCSemantic proximity Read

The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer.Semantic proximity Read

Mechanisms of osimertinib resistance and emerging treatment options.Semantic proximity Read

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read

Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer.Semantic proximity Read

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.Semantic proximity Read